A risk for hepatocellular carcinoma persists long-term after sustained virologic response in patients with hepatitis C-associated liver cirrhosis

Clinical Infectious Diseases

Volumn 57, Issue 2, 2013, Pages 230-236

  Aleman, Soo ^a   Rahbin, Nogol ^a   Weiland, Ola ^a   Davidsdottir, Loa ^a   Hedenstierna, Magnus ^a   Rose, Nina ^a   Verbaan, Hans ^b   Stål, Per ^a   Carlsson, Tony ^a   Norrgren, Hans ^b   Ekbom, Anders ^a   Granath, Fredrik ^a   Hultcrantz, Rolf ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

complications; hepatocellular carcinoma; liver decompensation; liver related death; sustained virologic response

Indexed keywords

PEGINTERFERON; RIBAVIRIN;

ADULT; ARTICLE; ASCITES; BLEEDING; CANCER RISK; CAUSE OF DEATH; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HEPATIC ENCEPHALOPATHY; HEPATITIS C; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LUNG CANCER; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PANCREAS CANCER; PANCREATITIS; PNEUMONIA; PRIORITY JOURNAL; PROSPECTIVE STUDY;

COMPLICATIONS; HEPATOCELLULAR CARCINOMA; LIVER DECOMPENSATION; LIVER-RELATED DEATH; SUSTAINED VIROLOGIC RESPONSE;

AGED; CARCINOMA, HEPATOCELLULAR; COHORT STUDIES; FEMALE; HEPATITIS C, CHRONIC; HUMANS; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; MIDDLE AGED; MULTICENTER STUDIES AS TOPIC; PROSPECTIVE STUDIES; RISK ASSESSMENT; TIME FACTORS; TREATMENT OUTCOME;

EID: 84879631408     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cit234     Document Type: Article

References (24)

1. Lok AS, Seeff LB, Morgan TR, et al. Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease. Gastroenterology 2009; 136:138-48.
2. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2012; 56:908-43.
3. FriedMW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347:975-82.
4. Hadziyannis SJ, Sette H Jr., Morgan TR, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: A randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140:346-55.
5. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial. Lancet 2001; 358:958-65.
6. Zeuzem S, Andreone P, Pol S, et al. Telaprevir for retreatment of HCV infection. N Engl J Med 2011; 364:2417-28.
7. Poordad F, McCone J Jr., Bacon BR, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364:1195-206.
8. Bruno S, Stroffolini T, Colombo M, et al. Sustained virological response to interferon-alpha is associated with improved outcome in HCVrelated cirrhosis: A retrospective study. Hepatology 2007; 45:579-87.
9. Veldt BJ, Heathcote EJ, Wedemeyer H, et al. Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis. Ann Intern Med 2007; 147:677-84.
10. Fernandez-Rodriguez CM, Alonso S, et al. Peginterferon plus ribavirin and sustained virological response in HCV-related cirrhosis: outcomes and factors predicting response. Am J Gastroenterol 2010; 105: 2164-72.
11. Bruno S, Crosignani A, Facciotto C, et al. Sustained virologic response prevents the development of esophageal varices in compensated, Child- Pugh class A hepatitis C virus-induced cirrhosis. A 12-year prospective follow-up study. Hepatology 2010; 51:2069-76.
12. Cardoso AC, Moucari R, Figueiredo-Mendes C, et al. Impact of peginterferon and ribavirin therapy on hepatocellular carcinoma: incidence and survival in hepatitis C patients with advanced fibrosis. J Hepatol 2010; 52:652-7.
13. Braks RE, Ganne-Carrie N, Fontaine H, et al. Effect of sustained virological response on long-term clinical outcome in 113 patients with compensated hepatitis C-related cirrhosis treated by interferon alpha and ribavirin.World J Gastroenterol 2007; 13:5648-53.
14. Lagging M, Duberg AS, Wejstål R, et al. Treatment of hepatitis C virus infection in adults and children: updated Swedish consensus recommendations. Scand J Infect Dis 2012; 44:502-21.
15. Bruix J, Sherman M. Management of hepatocellular carcinoma: An update, 2010. Available at: http://www.aasld.org/practiceguidelines/Documents/ HCCUpdate2010.pdf. Accessed 27 October 2012.
16. Mattsson B. Cancer registration in Sweden: studies on completeness and validity of incidence and mortality registers [PhD dissertation]. Stockholm, Sweden: Karolinska Institutet, 1984.
17. Syed E, Rahbin N, Weiland O, et al. Pegylated interferon and ribavirin combination therapy for chronic hepatitis C virus infection in patients with Child-Pugh class A liver cirrhosis. Scand J Gastroenterol 2008; 43:1378-86.
18. Morgan TR, Ghany MG, Kim HY, et al. Outcome of sustained virological responders with histologically advanced chronic hepatitis C. Hepatology 2010; 52:833-44.
19. Maruoka D, Imazeki F, Arai M, et al. Long-term cohort study of chronic hepatitis C according to interferon efficacy. J Gastroenterol Hepatol 2012; 27:291-9.
20. Ikeda K, Saitoh S, Arase Y, et al. Effect of interferon therapy on hepatocellular carcinogenesis in patients with chronic hepatitis type C: A longterm observation study of 1,643 patients using statistical bias correction with proportional hazard analysis. Hepatology 1999; 29:1124-30.
21. Yoshida H, Arakawa Y, Sata M, et al. Interferon therapy prolonged life expectancy among chronic hepatitis C patients. Gastroenterology 2002; 123:483-91.
22. Singal AK, Singh A, Jaganmohan S, et al. Antiviral therapy reduces risk of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis. Clin Gastroenterol Hepatol 2010; 8:192-9.
23. Singal AG, Volk ML, Jensen D, et al. A sustained viral response is associated with reduced liver-related morbidity and mortality in patients with hepatitis C virus. Clin Gastroenterol Hepatol 2010; 8:280-8.
24. Poynard T, McHutchison J, Davis GL, et al. Impact of interferon alfa- 2b and ribavirin on progression of liver fibrosis in patients with chronic hepatitis C. Hepatology 2000; 32:1131-7.